Table 2.
Hematological analysis among the patient and the control groups.
| Parameters | Controls | β-thalassemia homozygous | Sickle cell anemia patients | ||||
|---|---|---|---|---|---|---|---|
| Mean ± SD | TM, n: 27 Mean ± SD a |
TI, n: 50 Mean ± SD |
*P value 95% CI |
HbF ≤ 17.4% n: 50 Mean ± SD |
HbF > 17.4% n: 50 Mean ± SD |
**P value 95% CI |
|
| RBCs (106/µL) | 4.6 ± 0.6 | 2.8 ± 0.70 | 3.5 ± 0.69 | < 0.0001 | 3.1 ± 0.9 | 3.1 ± 0.9 | 0.5 |
| Hb (g/dL) | 13.5 ± 2.04 | 5.4 ± 1.17 | 7.8 ± 1.4 | < 0.0001 | 8.1 ± 2.1 | 9.1 ± 2.5 | 0.03 |
| MCV (fL) | 83.9 ± 4.2 | 75.1 ± 17.3 | 70.7 ± 7.8 | 0.92 | 79.4 ± 12.0 | 84.0 ± 10.6 | 0.04 |
| MCH (pg) | 28.9 ± 4.2 | 24.4 ± 5.2 | 22.8 ± 3.4 | 0.28 | 26.4 ± 4.4 | 29.2 ± 3.8 | 0.008 |
| MCHC (g/dL) | 34.5 ± 1.5 | 31.6 ± 3.5 | 32.2 ± 1.9 | 0.18 | 33.2 ± 2.1 | 34.8 ± 2.5 | 0.0003 |
| RDW (%) | 13.85 ± 1.5 | 32.8 ± 9.8 | 30.8 ± 5.9 | 0.36 | 22.8 ± 4.6 | 20.8 ± 6.3 | 0.0016 |
| Platelets (103/µL) | 291.7 ± 38.0 | 333 ± 246.8 | 370.8 ± 269 | 0.23 | 349.7 ± 211.1 | 221 ± 115.6 | 0.0002 |
| HbA2 (%) | 2.6 ± 0.2 | 3.6 ± 1.5 | 3.4 ± 1.9 | 0.08 | 3.0 ± 0.5 | 2.9 ± 1.1 | 0.007 |
| HbF (%) | 0.31 ± 0.2 | 65.6 ± 36.3 | 66.3 ± 34.2 | 0.46 | 12.7 ± 3.7 | 26.4 ± 7.1 | < 0.0001 |
| F-cells (%) | 2.4 ± 0.5 | 67.1 ± 26.01 | 68.0 ± 24.1 | 0.81 | 31.8 ± 18.6 | 43.2 ± 18.2 | 0.06 |
| HbS (%) | – | – | – | – | 74.1 ± 11.7 | 67.5 ± 9.4 | < 0.0001 |
*P value calculated among the β-thalassemia homozygous groups, **P value calculated among the SCA patient groups. The P value was calculated using unpaired non parametric Mann–Whitney U test.
aAt the time of testing 23 TM patients were on regular transfusions, hence these patients were excluded from hematological analysis.